SCHEMBL30737868

SCHEMBL30737868

COc1ccc(N2Cc3cnc(Nc4ccccc4)nc3N([C@@H]3CC[C@@H](O)C3)C2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 1.00
FGFR4 P22455 9/20 1.00
FGFR1 P11362 5/20 1.00
FGFR2 P21802 5/20 1.00
FGFR3 P22607 5/20 1.00
PDGFRB P09619 3/20 1.00
PDGFRA P16234 3/20 1.00
KDR P35968 3/20 1.00
FYN P06241 2/20 1.00
MAPK1 P28482 2/20 1.00
EPHB3 P54753 2/20 1.00
PRKACA P17612 1/20 0.85
PRKACG P22612 1/20 0.85
PRKACB P22694 1/20 0.85
CSF1R P07333 3/20 0.52
PRKDC P78527 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772113 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5832196 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5772118 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL27218145 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5811223 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL30737937 1.00 EGFR (1.00) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5831546 0.95 EGFR (0.90) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5767065 0.95 EGFR (0.90) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5830777 0.93 EGFR (0.87) EGFRFGFR4FGFR1FGFR2FGFR3
SCHEMBL5830774 0.93 EGFR (0.87) EGFRFGFR4FGFR1FGFR2FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO claimed
WO-2023240271-A1 USE OF VEGFR2 AND FGFR1 INHIBITORS IN THERAPY FOUNTAIN THERAPEUTICS INC. (US) 2023-12-14 WO disclosed